ace of pentacles wild unknown
Counter-terrorism police arrest seven in London raids connected to PKKOWINGS MILLS, Md. (AP) — In some sports, playing three games in 11 days would be considered a lull in the schedule. Football is different — although this type of stretch is becoming more common in the NFL. “I just kind of put myself in a basketball perspective. Those guys play back to back, so I guess there’s a little merit behind us quote-unquote complaining about it, but they are playing 82 games," Baltimore Ravens safety Kyle Hamilton said. “MLB players are playing 162 games, and we have 17, and we’re trying to fight them to go to 18 right now. I think it’s good in a sense that we’ll see who is most prepared down the stretch, and it’s really challenging for teams — everybody that’s involved.” The Ravens are one of the five teams that are about to go through a three-game, 11-day stretch. The Ravens, Chiefs, Steelers and Texans are playing Sunday, the following Saturday and then the Wednesday after that on Christmas. Chicago has a game this coming Monday night, then plays the following Sunday before a Thursday game on Dec. 26. Before this season, 21 teams in the Super Bowl era had played three games in 11 days, according to Sportradar. In 2024 there are nine stretches like that on the schedule. In addition to the five teams above, four others have already gone through a three-game, 11-day period. The Jets, Seahawks, Saints and Cowboys all had Monday-Sunday-Thursday runs like the Bears are about to face. The Jets and Cowboys managed to go 2-1 during those stretches, but the Seahawks and Saints went 0-3. “Try to win the first one, rest, try to get your body back how it should be,” Baltimore quarterback Lamar Jackson said. “If it’s not 100 percent, try to get it close as possible — just get ready to play football. That’s all.” For Baltimore, the easiest game of the three is in theory the first. As of Thursday afternoon, the Ravens were favored by 16 points at the New York Giants this weekend, according to BetMGM Sportsbook — but Baltimore has already lost to last-place teams like the Raiders and Browns this season. So the Ravens need to be careful not to overlook the lowly Giants. After the trip to New Jersey, Baltimore returns home to face Pittsburgh in a game that figures to be vital to the Ravens' AFC North title hopes. Then there's a road game against AFC South-leading Houston on Christmas. “The big picture is, ‘All hands on deck.’ We’re focused toward playing our best game so far on Sunday,” coach John Harbaugh said. “We’re going to need to do that, and that’s what we’re training and preparing to do. We have a plan for the three-game stretch, and that plan starts with Sunday.” The Ravens played on Christmas last year too, but that was on a Monday, so it wasn't that big a change in the schedule. If there's one factor in Baltimore's favor this season, it's that the Ravens had their open date last week — immediately before their rugged three-game stretch. But that meant Baltimore was among the last teams to have a week off. And the Ravens started earlier than almost anyone else, having been part of the NFL's opening game against Kansas City. “We reported to camp earlier than everybody else for that Thursday night game, and I think KC had their bye a little while ago,” Hamilton said. “I guess we had the longest stretch, continuous, of anybody else. It’s just going to be that much better at the end of it all, when we do what we need to do, and we can look back on that and say, ‘We did that, and we came out and won these three games.’” AP NFL: https://apnews.com/hub/nfl
Stock up on these popular board games for your next get-togetherTackling scams requires a team effort – but the EU is on track to create a blame game
Everything We Noticed in the Epic First Trailer for Superman
After a Snoop Dogg figurine and other merchandise was stolen from a St. Thomas games store earlier this week, its owners scored when their Facebook post motivated two shoplifters to return the items a day later. Marty Hancox, founder and co-owner of Fan of the Sport, was unpacking stock on Monday at the shop in the Elgin Centre shopping mall that sells sports memorabilia, trading cards and board games. He discovered a Pop Funko, a type of figurine depicting famous people and pop culture characters, was missing, said co-owner Dionne Turner, Hancox’s partner. After a search of the store failed to turn up the figurine of rapper Snoop Dogg, Hancox checked the store’s surveillance tapes, Turner said. The video showed that around 1:30 p.m., two females had pocketed the Snoop Dogg Pop Funko, a Pop Funko of X-Men character Wolverine, and a Toronto Maple Leafs coffee mug, Turner said. “I said, ‘I’m posting this online because we’ve had issues before,’” she said. “The police, they try to help, but there’s only so much they can do . . . and that’s how it all started.” This time, rather than contacting police, Turner and Hancox decided to post a video and several still images of the two females who had pocketed about $80 worth of merchandise to the store’s Facebook page around 4 p.m. on Monday, Turner said. Both Hancox and Turner said it wasn’t the cost of the items that motivated the post. Hancox said it was “more the principle of they took stuff” with Turner noting money is “out of our pocket ,too.” “We didn’t really like it, to kind of shame them on Facebook, but I thought, we’ll give it a try, and sure enough within 24 hours they contacted us,” Hancox said. He believes the pair were likely “getting pressure from family and friends” who saw their picture, he said. Turner said the two females returned the stolen property on Tuesday evening, and that the names of the shoplifters were never learned, nor were there were hard feelings. “I thanked them for bringing this stuff back,” Turner said, and told them she was “really impressed because it took a lot of guts to come in here and face me.” “We don’t care what their names are, we’re just happy we got our items back,” Hancox said. A spokesperson from the St. Thomas police stated by email that a property crime analyst with the department called shoplifters returning stolen property “very rare.” Turner said the shoplifters had mentioned they were having difficulty affording Christmas gifts, which she empathized with, but “they just went the wrong way about it. “I didn’t want them to get ostracized because everybody knew who they (are) now,” Turner said. “We got this stuff back, we’re going to drop it (and) hopefully they learned their lesson.” The post with the video and images of the shoplifters was removed and another was uploaded to Fan of the Sport’s Facebook page giving thanks to the pair for returning the stolen property and thanking customers and friends for sharing the post. The post has received an outpouring of support and even some kudos to the pair who returned the items. “Glad they came in and had a civil conversation and apologized,” wrote Facebook user Rebecaa Seeley. Tammy Crosby wrote: “That’s amazing news! That takes a lot of accountability on their part. Well done.” Turner appreciated the compassion for the two women as well. “I got teary eyed when I was reading the comments,” she said. “I was really, really impressed that everybody kind of supported them and agreed.”
Fresh off their open date, the Baltimore Ravens prepare for their schedule to become busy
Liverpool shines in Champions League, dumping Real Madrid down the table. Dortmund rises to 4th Liverpool stayed perfect in the Champions League. A 2-0 win at Anfield dumped title holder Real Madrid into an almost unbelievable 24th place in the 36-team standings. Liverpool's second half ghoals came from Alexis Mac Allister and Cody Gakpo, either side of Madrid superstar Kylian Mbappé having a penalty saved. Borussia Dortmund, is up to fourth place after beating Dinamo Zagreb 3-0. Monaco missed a chance to go second losing 3-2 at home to Benfica. The best comeback was at PSV Eindhoven. Te home team trailed Shakhtar Donetsk by two goals in the 87th minute of a 3-2 win. Daniel Jones is signing with the Vikings after his release from the Giants, AP source says A person familiar with the decision says former New York Giants quarterback Daniel Jones is signing with the Minnesota Vikings. The person spoke to The Associated Press on condition of anonymity because the agreement hasn’t been finalized. Jones will join Minnesota’s practice squad less than a week after the Giants released the former No. 6 overall draft pick. Sam Darnold has helped the Vikings start 9-2. Jones joins Nick Mullens and Brett Rypien in Minnesota’s quarterback room. Rookie first-round pick J.J. McCarthy had season-ending knee surgery in August and a second procedure on his knee earlier this month. LIV Golf will hire sports and entertainment leader Scott O'Neil to replace Greg Norman, report says Scott O'Neil is set to become the next CEO of Saudi-funded LIV Golf. The Athletic is reporting the move for the former head of the Philadelphia 76ers and New Jersey Devils. O'Neil recently was CEO of Merlin Entertainments. The company that owns resorts like Legoland announced O'Neil was leaving for a new opportunity. O'Neil would replace Greg Norman at LIV Golf. Sports Business Journal reported last month that Norman would move to a different role that has not been announced. Norman has been CEO of the rival golf league since it launched in 2022. The PGA Tour and Saudi backers are still negotiating an investment deal. West Virginia knocks off No. 3 Gonzaga 86-78 in overtime in the Battle 4 Atlantis NASSAU, Bahamas (AP) — Javon Small scored five of his 31 points in overtime and Tucker DeVries added key free throws late in regulation and finished with 16 points as West Virginia beat No. 3 Gonzaga 86-78 in the Battle 4 Atlantis. Small’s layup with under 2 minutes left in OT gave West Virginia a 79-75 lead. After a Gonzaga miss, Sencire Harris hit two free throws to make it a six-point lead. With 27.1 seconds left, Harris made a steal and scored on a dunk for an eight-point lead, putting the game out of reach. Braden Huff scored 19 points and Khalif Battle 16 for Gonzaga (5-1). Two companies drop McGregor after civil jury ruled he must pay $250K to woman who says he raped her LONDON (AP) — Two companies have cut ties with Conor McGregor after a civil court jury in Ireland ruled last week that he must pay nearly 250,000 Euros ($257,000) to a woman who accused the mixed martial arts fighter of raping her. Proximo Spirits, the owner of Irish whiskey brand Proper No. 12, will no longer feature McGregor’s name or image. Video game developer IO Interactive ended its collaboration with McGregor, who had played a character in a game. Nikita Hand said the Dec. 9, 2018, assault after a night of partying left her heavily bruised and suffering from post-traumatic stress disorder. McGregor said she fabricated the allegations after the two had consensual sex. Staley counsels some South Carolina fans to keep calm after No. 4 Gamecocks 1st loss in two seasons COLUMBIA, S.C. (AP) — South Carolina coach Dawn Staley is not in panic mode, even if some of famous “Fams” are following her team's first loss in two seasons. The Gamecocks had won 85 of their previous 86 games, including a program record 43 in a row before falling to UCLA 77-62 this past Sunday. South Carolina slipped from No. 1 to No. 4 in the rankings while the Bruins took over the top spot. Still, it caught Staley by surprise that some supporters were worried about the November loss. Staley said the defending national champions are still finding their way. Thanksgiving Weekend Sports Guide: Your roadmap to NFL matchups, with other games, times and odds The long sports-filled Thanksgiving weekend is a time when many Americans enjoy gathering with friends and family for good food, good company and hopefully not too much political conversation. Also on the menu — all the NFL and college sports you can handle. Here is a roadmap to one of the biggest sports weekends of the year, with a look at marquee games over the holiday and how to watch. Derrick Henry and Saquon Barkley prepare for earliest matchup ever between 1,300-yard running backs Saquon Barkley and Derrick Henry combined for 395 yards rushing on back-to-back nights at SoFi Stadium as the dynamic playmakers keep proving that investing in running backs can pay off in the right situation. Next, they will play on the same field at the same time when Barkley and the Philadelphia Eagles take on Henry and the Baltimore Ravens in the first matchup ever between two 1,300-yard runners in Week 13 or earlier. Before this year, no player had rushed for at least 1,300 yards and 10 TDs in the first 12 weeks of the season since Shaun Alexander in 2005 as teams moved away from bell-cow backs and diminished the importance of the position. Raiders will start O'Connell at quarterback when they visit the Chiefs HENDERSON, Nev. (AP) — Aidan O’Connell will start at quarterback when the Las Vegas Raiders visit their AFC West rival Kansas City Chiefs on Friday. Raiders coach Antonio Pierce says O’Connell had progressed well after breaking his right thumb on Oct. 20 in a game against the Los Angeles Rams. Gardner Minshew broke his left collarbone on Sunday in a game against the Denver Broncos and is out for the season. The Raiders could have gone with Desmond Ridder to replace Minshew. Luis Suarez signs to stay with Messi and Inter Miami for 2025 season FORT LAUDERDALE, Fla. (AP) — Luis Suarez is going to play alongside Lionel Messi for at least one more year. Suarez and Inter Miami have agreed on a one-year contract extension for the coming season, the team announced Wednesday. The financial terms weren’t disclosed. Suarez made $1.5 million this year in his first Inter Miami season, one in which the Uruguayan striker scored 20 goals — tied with Messi for the team lead — in Major League Soccer regular season play and a team-best 25 goals across all competitions.Martensville-Warman Early Years Family Resource Centre opens
Join MemryX at CES 2025 to Experience Edge AI Advantages offered by the MX3 AI AcceleratorSouth Texas groups sue state agency for allowing SpaceX to discharge industrial water without permit
Seplat Energy Plc has been named the Best In Social Impact/Human Capacity Development at the Sustainability, Enterprise and Responsibility Awards (SERAS) Africa for 2024, according to a statement on Thursday. The statement said the company was announced as the winner of the award at the 18th edition of the SERAS Africa held at the Oriental Hotel in Lagos. The organisers were said to have lauded Seplat Energy’s corporate social investment programmes in the health, education and entrepreneurship spheres as well as the programmes’ strong impacts in Seplat Energy’s host communities and states. “The SERAS Africa is an annual project which aims to promote as well as raise awareness about the roles that organisations play with the emphasis on their responsibility towards stakeholders and the social development of Africa. It aims to substantiate the case that corporations who are socially responsible stand to gain huge benefits with regards to economic, social and environmental capital,” the statement added. According to the organisers, Seplat Energy educational programmes are in alignment with the United Nations sustainable development goals/objectives 1, 3 & 4 (SDGs 1,3 & 4); which aim for poverty reduction/eradication, healthy lives for all, and access to quality education. Some of the programmes executed by Seplat Energy in this regard are: Seplat Teachers Empowerment Programme (STEP), PEARLs Quiz, Seplat National Undergraduate Scholarships, Seplat Innovation Programme, and Seplat JV Eye Can See programme. The STEP program equips teachers and Chief Inspectors of Education with digital teaching skills, leadership training, and income diversification skills. Through the Seplat PEARLs Quiz, scholarships have been awarded to winning secondary school students; and contributed directly to improving the infrastructure of secondary schools by awarding prize money to winning secondary schools. The Seplat National Undergraduate Scholarship began in 2014 for host communities, states, and the nation. Since then, the company has provided scholarships to Federal and State University undergraduate students of which a significant percentage are from our host communities. The Seplat Innovators Programme is creating STEAM Laboratories which are collaborative spaces where the study of science, technology, engineering, arts and mathematics can be integrated through hands-on experiences in a pure laboratory or combined classroom-laboratory setting. The Seplat JV Eye Can See programme has been delivering critical eye care services—free screenings, surgeries, and distribution of eyeglasses—to thousands of underserved residents, reaffirming the joint venture’s unwavering commitment to improving healthcare access in its host communities. Commenting on the award, the founder of SERAS Africa, Ken Egbas, said all awardees have shown exemplary commitment and leadership in driving sustainability across the continent; of which their contributions must be recognised, rewarded and celebrated. The ceremony had in attendance companies from all sectors across African economies, industry regulators, not-for-profit organisations, public sector players, and media, amongst other stakeholders.Esusu Creates Over $46.9 Billion in New Credit Tradelines for Renters Across the Country
CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.None